8 results
The objectives are:1. Compare how the body processes single and multiple doses of tapentadol for a certain period after taking the tablets. This way absorption, excretion and distribution of the drug in the body is assessed.2. Findings of the safety…
1. Measure DNIC and offset analgesia in neuropathic pain patients;2. Compare DNIC and offset analgesia in chronic pain patients with DNIC and offset analgesia in healthy volunteers;3. Assess the effect of oral tapentadol on DNIC and offset analgesia…
The primary hypothesis of this study is that a dose-response relationship exists between disease activity as measured by the change from baseline in the Mayo score at Week 8 and JNJ-54781532 treatment regimens in subjects with moderately to severely…
The objective of this study is to investigate the extent of respiratory depression at equi-analgesic dosages of tapentadol and oxycodone
(1) To phenotype chronic low back pain patients in terms of endogenous modulation of pain, central sensitization/facilitation, and the presence of a neuropathic pain component;(2) To assess the effect of a three-month treatment with tapentadol on…
To construct the utility surfaces of tapentadol and oxycodone.
(1) To phenotype fibromyalgia patients in terms of endogenous modulation of pain, central sensitization/facilitation, the presence of a neuropathic pain component and small fiber neuropathy;(2) To assess the effect of a three-month treatment with…
The purpose of this study is to investigate how quickly and to what extent two 25 mg prolonged release tapentadol tablets are absorbed and eliminated from the body (this is called pharmacokinetics) when compared to one 50 mg prolonged release…